Torrent’s Brazil Growth Surges 36% In Q3
German Market Recovers Slightly While India Holds Steady
Executive Summary
Torrent’s quarterly revenues were up by 18% to INR24.9bn in Q3 FY2023. Branded generics and the Brazilian market did much of the heavy lifting.
You may also be interested in...
India And Brazil Sustain Branded Generics Success For Torrent In Q2
Torrent continues its overall growth trajectory in Q2 of its 2023 financial year, but a flagging German market slows the company’s expansion strategy. The board insists improved sales are just around the corner.
US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance
While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.
Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India
Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.